Oxurion NV (OXUR.BR)

EUR 0.08

(-2.44%)

Net Debt Summary of Oxurion NV

Oxurion NV's latest annual net debt in 2023 was 10.71 Million EUR , up 136.95% from previous year.
Oxurion NV's latest quarterly net debt in 2024 Q2 was 11.55 Million EUR , down 0.0% from previous quarter.
Oxurion NV reported annual net debt of 4.52 Million EUR in 2022, up 91.61% from previous year.
Oxurion NV reported annual net debt of 2.35 Million EUR in 2021, up 110.07% from previous year.
Oxurion NV reported quarterly net debt of 10.71 Million EUR for 2023 FY, up 136.95% from previous quarter.
Oxurion NV reported quarterly net debt of 10.71 Million EUR for 2023 Q4, down 0.0% from previous quarter.

Annual Net Debt Chart of Oxurion NV (2023 - 2006)

Historical Annual Net Debt of Oxurion NV (2023 - 2006)

Year	Net Debt	Net Debt Growth
2023	10.71 Million EUR	136.95%
2022	4.52 Million EUR	91.61%
2021	2.35 Million EUR	110.07%
2020	-23.41 Million EUR	41.84%
2019	-40.25 Million EUR	37.73%
2018	-64.65 Million EUR	-15.09%
2017	-56.17 Million EUR	3.56%
2016	-58.25 Million EUR	37.59%
2015	-93.34 Million EUR	24.25%
2014	-123.22 Million EUR	25.12%
2013	-164.57 Million EUR	-18.06%
2012	-139.39 Million EUR	-142.23%
2011	-57.54 Million EUR	32.98%
2010	-85.86 Million EUR	-13.09%
2009	-75.92 Million EUR	-150.13%
2008	-30.35 Million EUR	24.32%
2007	-40.11 Million EUR	-25.18%
2006	-32.04 Million EUR	0.0%

Year	Net Debt	Net Debt Growth
2024 Q2	11.55 Million EUR	0.0%
2023 FY	10.71 Million EUR	136.95%
2023 Q4	10.71 Million EUR	0.0%
2023 Q2	8.76 Million EUR	0.0%
2022 Q4	4.52 Million EUR	0.0%
2022 Q2	4.35 Million EUR	0.0%
2022 FY	4.52 Million EUR	91.61%
2021 FY	2.35 Million EUR	110.07%
2021 Q2	-9.02 Million EUR	0.0%
2021 Q4	2.35 Million EUR	0.0%
2020 Q4	-23.41 Million EUR	0.0%
2020 Q2	-25.7 Million EUR	0.0%
2020 FY	-23.41 Million EUR	41.84%
2019 Q2	-44.66 Million EUR	0.0%
2019 FY	-40.25 Million EUR	37.73%
2019 Q4	-40.25 Million EUR	0.0%
2018 Q4	-64.65 Million EUR	0.0%
2018 FY	-64.65 Million EUR	-15.09%
2018 Q2	-75.79 Million EUR	0.0%
2017 Q2	-43.41 Million EUR	0.0%
2017 FY	-56.17 Million EUR	3.56%
2017 Q4	-56.17 Million EUR	0.0%
2016 FY	-58.25 Million EUR	37.59%
2016 Q4	-58.25 Million EUR	0.0%
2016 Q2	-66.98 Million EUR	0.0%
2015 Q2	-112.4 Million EUR	0.0%
2015 FY	-93.34 Million EUR	24.25%
2015 Q4	-93.34 Million EUR	0.0%
2014 Q2	-131.97 Million EUR	0.0%
2014 FY	-123.22 Million EUR	25.12%
2014 Q4	-123.22 Million EUR	0.0%
2013 Q2	-185.66 Million EUR	0.0%
2013 FY	-164.57 Million EUR	-18.06%
2013 Q4	-164.57 Million EUR	0.0%
2012 Q2	-177.25 Million EUR	0.0%
2012 FY	-139.39 Million EUR	-142.23%
2012 Q4	-139.39 Million EUR	0.0%
2011 Q2	-95.62 Million EUR	0.0%
2011 FY	-57.54 Million EUR	32.98%
2011 Q4	-57.54 Million EUR	0.0%
2010 FY	-85.86 Million EUR	-13.09%
2010 Q4	-85.86 Million EUR	0.0%
2010 Q2	-57.96 Million EUR	0.0%
2009 FY	-75.92 Million EUR	-150.13%
2009 Q4	-75.92 Million EUR	0.0%
2008 FY	-30.35 Million EUR	24.32%
2007 FY	-40.11 Million EUR	-25.18%
2006 FY	-32.04 Million EUR	0.0%

Peer Net Debt Comparison of Oxurion NV

Name	Net Debt	Net Debt Difference
Nicox S.A.	13.89 Million EUR	22.916%
European Medical Solutions	13.93 Million EUR	23.121%
FERMENTALG	4.19 Million EUR	-155.426%
argenx SE	-1.83 Billion EUR	100.583%
BioSenic S.A.	28.04 Million EUR	61.81%
Celyad Oncology SA	-6.1 Million EUR	275.516%
Hyloris Pharmaceuticals SA	-25.11 Million EUR	142.649%
Onward Medical N.V.	-12.89 Million EUR	183.062%
PHAXIAM Therapeutics S.A.	-275 Thousand EUR	3994.545%
Financière de Tubize SA	78.62 Million EUR	86.378%
UCB SA	2.17 Billion EUR	99.508%